Brandywine Global Investment Management, LLC Intra Cellular Therapies, Inc. Transaction History

Brandywine Global Investment Management, LLC

$14.2 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$43.0 - $65.64 $23.1 Million - $35.3 Million	-537,279 Reduced 94.46%	31,532 $1.8 Million
Q1 2022 May 13, 2022	SELL	$38.74 - $62.09 $238,909 - $382,909	-6,167 Reduced 1.07%	568,811 $34.8 Million
Q4 2021 Feb 11, 2022	SELL	$35.2 - $53.42 $355,379 - $539,328	-10,096 Reduced 1.73%	574,978 $30.1 Million
Q3 2021 Nov 12, 2021	BUY	$28.72 - $42.49 $11.2 Million - $16.6 Million	389,514 Added 199.18%	585,074 $21.8 Million
Q2 2021 Aug 13, 2021	BUY	$29.3 - $44.5 $5.73 Million - $8.7 Million	195,560 New	195,560 $7.98 Million
Q1 2020 May 15, 2020	SELL	$12.31 - $33.12 $807,769 - $2.17 Million	-65,619 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.26 - $38.49 $58,530 - $310,306	8,062 Added 14.01%	65,619 $2.17 Million
Q3 2019 Nov 14, 2019	SELL	$7.47 - $14.03 $99,440 - $186,767	-13,312 Reduced 18.78%	57,557 $430,000
Q2 2019 Aug 14, 2019	BUY	$10.65 - $14.29 $302,555 - $405,964	28,409 Added 66.91%	70,869 $920,000
Q1 2019 May 15, 2019	BUY	$10.9 - $14.09 $462,814 - $598,261	42,460 New	42,460 $518,000

Others Institutions Holding ITCI

# of Institutions

380

Shares Held

84M

Call Options Held

319K

Put Options Held

143K

Vanguard Group Inc Valley Forge, PA

9.63M
Shares

$1.22 Billion
0.01% of portfolio
Black Rock Inc. New York, NY

6.32M
Shares

$803 Million
0.01% of portfolio
Jpmorgan Chase & CO New York, NY

5.29M
Shares

$671 Million
0.03% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

3.85M
Shares

$489 Million
1.4% of portfolio
Avoro Capital Advisors LLC New York, NY

3.05M
Shares

$387 Million
3.36% of portfolio

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brandywine Global Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brandywine Global Investment Management, LLC with notifications on news.

Account